Syndax Pharmaceuticals Expands Revuforj Access, Receives Price Target Increase
Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.
On January 7, Syndax Pharmaceuticals partnered with the World Orphan Drug Alliance to launch a Managed Access Program for Revuforj (revumenib), its first-in-class menin inhibitor. This initiative will provide a pathway for physicians to prescribe the medication to patients in regions where it is not yet commercially available.
The program will operate in parts of Eurasia, Central and Southeast Europe, the Middle East, Israel, Turkey, Latin America, and Africa. The program is designed to operate within local regulatory frameworks and requires secured funding for patients with rare and life-threatening blood cancers. The collaboration aims not only to bridge the current access gap for innovative oncology treatments but also to allow international physicians to gain firsthand clinical experience with the drug.
In the US, Revuforj is already FDA-approved for treating adult and pediatric patients with relapsed or refractory acute leukemia involving a KMT2A translocation or NPM1 mutation. These conditions are typically associated with a poor prognosis and limited treatment options.
On February 3, a firm raised its price target on Syndax to $28 from $27 and kept a Buy rating. The firm noted that due to the volume of pre-announcements, upcoming Q4 2025 earnings may not have the same impact as in prior years.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer. The company's shares showed a 90 day share price return of 19.21% and 1 year total shareholder return of 37.27%, though recent performance included a 1 day share price return of a 3.12% decline and a 7 day share price return of a 2.52% decline. At a last close of $20.48, the company's shares were trading below certain price targets.
Syndax appeared at the Guggenheim Securities Emerging Outlook Biotech Summit 2026, following positive Revuforj trial data and the announcement of the new Managed Access Program.